Wolverine Trading
VKTX icon

Wolverine Trading’s Viking Therapeutics VKTX Stock Holding History

Wolverine Trading’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.81M Hold
109,000
– – ﹤0.01% 1877
2025
Q2 		$2.89M Sell
109,000
-27,500
-20% -$724K ﹤0.01% 1415
2025
Q1 		$3.5M Buy
136,500
+14,300
+12% +$452K ﹤0.01% 1225
2024
Q4 		$4.86M Buy
122,200
+6,900
+6% +$393K ﹤0.01% 1226
2024
Q3 		$7.11M Buy
115,300
+49,900
+76% +$2.93M 0.01% 858
2024
Q2 		$3.47M Sell
65,400
-21,600
-25% -$1.42M ﹤0.01% 1206
2024
Q1 		$7.13M Buy
87,000
+52,200
+150% +$2.32M 0.01% 807
2023
Q4 		$648K Buy
34,800
+15,800
+83% +$207K ﹤0.01% 2694
2023
Q3 		$210K Sell
19,000
-33,900
-64% -$485K ﹤0.01% 3705
2023
Q2 		$826K Sell
52,900
-16,000
-23% -$335K ﹤0.01% 2162
2023
Q1 		$1.19M Buy
68,900
+32,600
+90% +$337K ﹤0.01% 1751
2022
Q4 		$341K Buy
+36,300
New +$162K ﹤0.01% 2657
2022
Q2 		– Sell
-12,700
Closed -$39K – 5813
2022
Q1 		$39K Sell
12,700
-6,700
-35% -$24K ﹤0.01% 5142
2021
Q4 		$90K Buy
+19,400
New +$109K ﹤0.01% 5138
2021
Q3 		– Sell
-17,500
Closed -$108K – 7026
2021
Q2 		$108K Buy
17,500
+300
+2% +$1.78K ﹤0.01% 5372
2021
Q1 		$104K Buy
+17,200
New +$121K ﹤0.01% 5422
2020
Q4 		– Sell
-22,700
Closed -$135K – 5539
2020
Q3 		$135K Sell
22,700
-200
-0.9% -$1.38K ﹤0.01% 4027
2020
Q2 		$166K Sell
22,900
-8,800
-28% -$58.4K ﹤0.01% 3932
2020
Q1 		$150K Buy
+31,700
New +$195K ﹤0.01% 3826
2019
Q4 		– Sell
-38,600
Closed -$268K – 5273
2019
Q3 		$268K Buy
+38,600
New +$287K ﹤0.01% 3282
2019
Q1 		– Sell
-89,000
Closed -$674K – 5379
2018
Q4 		$674K Sell
89,000
-38,600
-30% -$462K ﹤0.01% 2352
2018
Q3 		$2.22M Buy
+127,600
New +$1.52M ﹤0.01% 1572

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wolverine Trading's VKTX Position: Q3 2025 in Review

Wolverine Trading reduced its Viking Therapeutics (VKTX) stake by 81% in Q3 2025, selling an estimated $1.05M and leaving 8,486 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #4815.

Wolverine Trading first reported a position in VKTX in Q3 2018 and has held it in 16 quarters since. The position peaked at $3.42M in Q3 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Wolverine Trading held 8,486 shares of Viking Therapeutics worth $219K as of Q3 2025.
  • Wolverine Trading sold 35,333 Viking Therapeutics shares in Q3 2025, an estimated $1.05M.
  • Viking Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4815 holding.
  • Wolverine Trading first reported a position in Viking Therapeutics in Q3 2018 and has held it in 16 quarters since.
  • Wolverine Trading's Viking Therapeutics position peaked at $3.42M in Q3 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.